ASCO 2021 Highlights From IMpower 010 on Resected Stage IB-IIIA NSCLC: Atezolizumab vs. BSC After Adjuvant Chemotherapy

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

City of Hope

www.cityofhope.org

Breast
Lung
Gastrointestinal
Genitourinary
Gynecologic Oncology
Leukemia
Lymphoma
Myeloma
Hematologic Malignancies
Head and Neck
General Oncology
Palliative Care
Events

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ASCO 2021 Highlights From IMpower 010 on Resected Stage IB-IIIA NSCLC: Atezolizumab vs. BSC After Adjuvant Chemotherapy

By City of Hope FEATURING Jack West

585 views

July 1, 2021

This video was recorded prior to the FDA granting approval to Atezolizumab on 10/15/2021 as ...
read more ↘ adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC
↖ read less

Comments 0

Insights on Proteasome Inhibitor Combinations at First Relapse in Mu…

Feat. M. Levy

Lung

WCLC 2024 Insights: Management of Radiation Toxicities in The Era of…

Insights from 2024 WCLC

P. Lee

101 views

Immunotherapy for SCLC - Best of Lung 2023

Total Health

J. Malhotra

119 views

Updates on Universal Comprehensive Genomic Profiling & Treatment Pla…

Total Health

R. Salgia

134 views

Novel Approaches in the Treatment of NSCLC

Total Health

E. Massarelli

359 views

ASCO® 2023 Insights: "LUNAR Trial Key Learnings & Clinical Implicati…

Insights from 2023 ASCO® Annual Meeting

J. West

51 views

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Clinical Imp…

Insights from 2023 ASCO® Annual Meeting

J. West

964 views

Prevalence of EGFR Mutation Testing in Early Stage Lung Cancer: Impl…

City of Hope

E. Massarelli

183 views